Reversing Immune Aging To Improve Immunotherapy Outcomes
As we age, our immune system naturally declines, a process called immunosenescence. This decline can make older individuals more susceptible to infections and reduce the effectiveness of certain cancer treatments, particularly immunotherapies. Immunotherapies are treatments that harness the body’s own immune system to fight cancer, and a type called checkpoint inhibitors works by “taking the brakes off” immune cells, allowing them to attack tumors.
Researchers have been exploring ways to rejuvenate the aging immune system to enhance the benefits of these life-saving cancer treatments. One promising approach involves using messenger RNA (mRNA) to deliver instructions to cells, prompting them to produce specific proteins that can restore immune function. Another strategy focuses on senolytics, which are drugs designed to selectively eliminate senescent cells—cells that have stopped dividing but remain active and can contribute to inflammation and suppress immune responses.
In a recent study, scientists identified key immune signaling pathways (Notch, FLT3, and IL7) that typically weaken with age. To counteract this, they used tiny fat-based particles, called lipid nanoparticles, to deliver mRNA encoding three “trophic factors” (substances that promote cell growth and function) to liver cells. This innovative treatment in mice led to a significant expansion of early-stage immune cells in the bone marrow and boosted the function of the thymus, an organ crucial for the maturation of T cells, which are vital immune cells.
The treated mice showed an increase in naive T cells (immune cells ready to respond to new threats) and improved function of dendritic cells (immune cells that help activate T cells). Furthermore, their tumors had more CD8+ T cells, which are specialized immune cells that kill cancer cells, and these T cells showed fewer signs of exhaustion and greater diversity in their receptors, allowing them to recognize a wider range of cancer cells. Remarkably, when combined with a checkpoint inhibitor, this immune-rejuvenating treatment resulted in complete tumor regression in 40% of the mice, a outcome not seen with the checkpoint inhibitor alone.
These findings suggest that by directly addressing age-related immune decline, we could significantly improve how well immunotherapies work for older cancer patients. Human trials are currently underway to investigate these strategies further.
Source: link to paper